{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.9"},{"groupId":"OG001","value":"26.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"},{"groupId":"OG001","value":"135"}],"units":"Participants"}],"description":"Confirmed PSA response is defined as ≥ 50% reduction in PSA from baseline on at least two assessments conducted at least 3 weeks apart. PSA response is calculated for all participants with PSA values at baseline and at least one post-baseline assessment. PSA is assessed by a local laboratory.","groups":[{"description":"Oral rucaparib (monotherapy).\n\nRucaparib: Rucaparib will be administered daily.","id":"OG000","title":"Rucaparib"},{"description":"Oral abiraterone acetate (monotherapy, given in combination with prednisone). Oral enzalutamide (monotherapy). Intravenous docetaxel (monotherapy, given in combination with prednisone or prednisolone).\n\nAbiraterone acetate or Enzalutamide or Docetaxel: Abiraterone acetate and enzalutamide will be administered daily.\n\nDocetaxel will be administered every 3 weeks.","id":"OG001","title":"Abiraterone Acetate or Enzalutamide or Docetaxel"}],"paramType":"NUMBER","populationDescription":"ITT Population included all randomized participants (participants with BRCA mutated mCRPC and participants with ATM mutated mCRPC).","reportingStatus":"POSTED","timeFrame":"From enrollment to primary completion of study (up to approximately 5 years)","title":"PSA Response in Participants With a BRCA or ATM Alteration Combined","type":"SECONDARY","unitOfMeasure":"percentage of participants"}